Zhonghua fu chan ke za zhi · 2000
[High-dose chemotherapy with peripheral-blood stem cells transplantation in patients with advanced gynecological malignant tumors].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang H, Huang R, Pan L
Аннотация
OBJECTIVE: To evaluate the clinical effectiveness of high dose chemotherapy(HDC) with peripheral-blood stem cells transplantation(PBSCT) in the patients with advanced malignant tumors.
METHODS: Four patients with advanced or refractory ovarian carcinoma and 1 patient with recurrent fallopian tube carcinoma received the HDC with PBSCT after optimal tumor debulking. Of whom 4 patients were with the recurrent or progressive tumors, 1 patient received HDC as primary chemotherapy. The response and toxicity were assessed after treatment.
RESULTS: Among 5 patients, four patients are survival. One case died from the recurrence of juvenile granulosa cell tumor. The average survival periods were 21 months. The tumors were all recurrent among the 4 survival patients. The average periods of recurrence after HDC treatment was 9 months. The main toxicity of HDC was severe marrow suppression. The lowest value of the neutrophil count and platelet count was 0.05-0.2 x 10(9)/L and 7 x 10(9)/L-8 x 10(9)/L respectively. The median time to recover a neutrophil count greater than 0.5 x 10(9)/L was 14 days and a platelet count greater than 50 x 10(9)/L was 17 days. None of the patients was complicated with severe complications.
CONCLUSIONS: HDC and PBSCT used for ovarian carcinoma was flexibility and security if the patient was selected strictly though its toxicity was severe. Further study among the chemorefactory recurrent patients need to try in the future.
METHODS: Four patients with advanced or refractory ovarian carcinoma and 1 patient with recurrent fallopian tube carcinoma received the HDC with PBSCT after optimal tumor debulking. Of whom 4 patients were with the recurrent or progressive tumors, 1 patient received HDC as primary chemotherapy. The response and toxicity were assessed after treatment.
RESULTS: Among 5 patients, four patients are survival. One case died from the recurrence of juvenile granulosa cell tumor. The average survival periods were 21 months. The tumors were all recurrent among the 4 survival patients. The average periods of recurrence after HDC treatment was 9 months. The main toxicity of HDC was severe marrow suppression. The lowest value of the neutrophil count and platelet count was 0.05-0.2 x 10(9)/L and 7 x 10(9)/L-8 x 10(9)/L respectively. The median time to recover a neutrophil count greater than 0.5 x 10(9)/L was 14 days and a platelet count greater than 50 x 10(9)/L was 17 days. None of the patients was complicated with severe complications.
CONCLUSIONS: HDC and PBSCT used for ovarian carcinoma was flexibility and security if the patient was selected strictly though its toxicity was severe. Further study among the chemorefactory recurrent patients need to try in the future.